Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study.

Nagarajah J, Ho AL, Tuttle RM, Weber WA, Grewal RK.

J Nucl Med. 2015 May;56(5):662-7. doi: 10.2967/jnumed.114.150607. Epub 2015 Mar 26.

2.

Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas.

Yoon M, Jung SJ, Kim TH, Ha TK, Urm SH, Park JS, Lee SM, Bae SK.

Endocr Res. 2016;41(1):64-9. doi: 10.3109/07435800.2015.1066803. Epub 2015 Oct 29.

PMID:
26513490
3.

Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer.

Yoon S, An YS, Lee SJ, So EY, Kim JH, Chung YS, Yoon JK.

Medicine (Baltimore). 2015 Dec;94(48):e2063. doi: 10.1097/MD.0000000000002063.

4.

THE RELATIONSHIP OF BRAFV600E MUTATION STATUS TO FDG PET/CT AVIDITY IN THYROID CANCER: A REVIEW AND META-ANALYSIS.

Santhanam P, Khthir R, Solnes LB, Ladenson PW.

Endocr Pract. 2018 Jan;24(1):21-26. doi: 10.4158/EP-2017-0080. Epub 2017 Nov 16. Review.

PMID:
29144823
5.

Relationship Between 18F-fluorodeoxyglucose Accumulation and the BRAF V600E Mutation in Papillary Thyroid Cancer.

Chang JW, Park KW, Heo JH, Jung SN, Liu L, Kim SM, Kwon IS, Koo BS.

World J Surg. 2018 Jan;42(1):114-122. doi: 10.1007/s00268-017-4136-y.

PMID:
28808756
6.

Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.

Choi EK, Chong A, Ha JM, Jung CK, O JH, Kim SH.

Clin Endocrinol (Oxf). 2017 Jul;87(1):73-79. doi: 10.1111/cen.13335. Epub 2017 Apr 18.

PMID:
28329426
7.

Correlation of BRAF mutation and SUVmax levels in thyroid cancer patients incidentally detected in 18F-fluorodeoxyglucose positron emission tomography.

Ozderya A, Temizkan S, Gul AE, Ozugur S, Sargin M, Aydin K.

Endocrine. 2017 Jan;55(1):215-222. doi: 10.1007/s12020-016-1128-x. Epub 2016 Oct 1.

PMID:
27696232
8.

Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.

Grabellus F, Nagarajah J, Bockisch A, Schmid KW, Sheu SY.

Clin Nucl Med. 2012 Feb;37(2):121-7. doi: 10.1097/RLU.0b013e3182393599.

PMID:
22228332
9.

BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability.

Barollo S, Pennelli G, Vianello F, Watutantrige Fernando S, Negro I, Merante Boschin I, Pelizzo MR, Rugge M, Mantero F, Nacamulli D, Girelli ME, Busnardo B, Mian C.

Eur J Endocrinol. 2010 Oct;163(4):659-63. doi: 10.1530/EJE-10-0290. Epub 2010 Jul 20.

PMID:
20647301
10.

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA.

Cancer Res. 2009 Jun 1;69(11):4885-93. doi: 10.1158/0008-5472.CAN-09-0727.

11.

Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma.

Kim MH, Ko SH, Bae JS, Lee SH, Jung CK, Lim DJ, Baek KH, Kim SH, Lee JM, Kang MI, Cha BY.

Thyroid. 2013 Nov;23(11):1452-60. doi: 10.1089/thy.2013.0051. Epub 2013 Sep 19.

PMID:
23688271
12.

Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer.

Murugan AK, Qasem E, Al-Hindi H, Shi Y, Alzahrani AS.

J Transl Med. 2016 Jul 7;14(1):204. doi: 10.1186/s12967-016-0958-x.

13.

Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma.

Schmitt RJ, Kreidler SM, Glueck DH, Amaria RN, Gonzalez R, Lewis K, Bagrosky BM, Kwak JJ, Koo PJ.

Nucl Med Commun. 2016 Feb;37(2):122-8. doi: 10.1097/MNM.0000000000000406.

14.

BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer.

Zerilli M, Zito G, Martorana A, Pitrone M, Cabibi D, Cappello F, Giordano C, Rodolico V.

Mod Pathol. 2010 Aug;23(8):1052-60. doi: 10.1038/modpathol.2010.86. Epub 2010 May 14.

15.

Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.

Lee MH, Lee SE, Kim DW, Ryu MJ, Kim SJ, Kim SJ, Kim YK, Park JH, Kweon GR, Kim JM, Lee JU, De Falco V, Jo YS, Shong M.

J Clin Endocrinol Metab. 2011 Jan;96(1):E19-30. doi: 10.1210/jc.2010-1071. Epub 2010 Oct 6.

PMID:
20926530
16.

Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer.

Kawada K, Nakamoto Y, Kawada M, Hida K, Matsumoto T, Murakami T, Hasegawa S, Togashi K, Sakai Y.

Clin Cancer Res. 2012 Mar 15;18(6):1696-703. doi: 10.1158/1078-0432.CCR-11-1909. Epub 2012 Jan 26.

17.

The usefulness of standardized uptake value in differentiation between benign and malignant thyroid lesions detected incidentally in 18F-FDG PET/CT examination.

Stangierski A, Woliński K, Czepczyński R, Czarnywojtek A, Lodyga M, Wyszomirska A, Janicka-Jedyńska M, Bączyk M, Ruchała M.

PLoS One. 2014 Oct 8;9(10):e109612. doi: 10.1371/journal.pone.0109612. eCollection 2014.

18.

Diagnostic value of metabolic tumor volume assessed by 18F-FDG PET/CT added to SUVmax for characterization of thyroid 18F-FDG incidentaloma.

Kim BH, Kim SJ, Kim H, Jeon YK, Kim SS, Kim IJ, Kim YK.

Nucl Med Commun. 2013 Sep;34(9):868-76. doi: 10.1097/MNM.0b013e328362d2d7.

PMID:
23797273
19.

Clinical value of visually identifiable 18F-fluorodeoxyglucose uptake in primary papillary thyroid microcarcinoma.

Hwang SO, Lee SW, Kang JK, Choi HH, Kim WW, Park HY, Jung JH.

Otolaryngol Head Neck Surg. 2014 Sep;151(3):415-20. doi: 10.1177/0194599814537224. Epub 2014 Jun 5.

PMID:
24903453
20.

Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients.

Pryma DA, Schöder H, Gönen M, Robbins RJ, Larson SM, Yeung HW.

J Nucl Med. 2006 Aug;47(8):1260-6.

Supplemental Content

Support Center